News Column

Global Healthcare Environment Strategy Firm appoints British Medical Research Expert as its European Director

July 30, 2014



Dr Steven Bradshaw (http://www.drstevenbradshaw.com/), a medical research expert, has been appointed as the European Director of a leading global healthcare environment strategy consulting firm, Market Access Solutions (http://www.mktxs.com/) (MKTXS). MKTXS provides consulting services on market access, health economics, outcomes research, product pricing and portfolio evaluations to the world’s top healthcare technology companies. It helps technology companies to understand, establish and communicate their product’s clinical and economic value, to facilitate market access at the optimal price.

Dr Bradshaw has over 15 years’ experience in the healthcare industry and has an extensive practical understanding of the real-world issues facing patients, payers, providers and pharma.

The appointment as the European Director for MKTXS is as a remarkable recognition for Dr Bradshaw’s dedications and contributions to the healthcare sector. Before MKTXS, Dr Bradshaw was Asia-Pacific Lead and Medical Advisor at Evidera. He was formerly Senior Global Market Access Consultant at United BioSource Corporation (UBC).

Dr Bradshaw commented on the news: “It’s a great honour to be appointed as the European Director for MKTXS. As a former physician in the UK National Health Service for over eight years, I understand how new health technologies can bring benefits to patients; optimal market access is central to the success of the healthcare industry and to patient outcomes.

"The entire development process for a medicinal product can take 12 to 15 years and a typical investment of over £1 billion. Companies can only make these substantial investments when they have enough certainty about topics such as unmet clinical need, market size and market access. We need to encourage the expertise within this particular sector to grow: understanding how changing global healthcare environments and data requirements can affect the uptake of a new product is fundamental to help support the industry in bringing better medicines and technologies to patients.

"There are many exciting medicines in development, some to treat conditions where there were previously no effective therapies available; although there are initiatives to fast track certain medicines to patients, there is still a lag that occurs between having a product approved by the European regulator (the European Medicines Agency) and having the treatment available at the bedside.

“Before new products can reach patients, industry must understand the different stakeholders in each market, and provide the right data, to the right stakeholders with the right message, communicated in the right language, at the right time, and the product needs to be at the right price.

“At MKTXS, we have a high calibre team to provide integrated research and healthcare analytic strategies to help our clients solve complex market access challenges and equip them with the tools they need to develop and optimise their assets and prepare for product launch and beyond. Our European office is a key part of our growth as we develop innovative and forward-thinking business solutions that provide our clients with actionable insights they need to succeed in the healthcare marketplace of today and tomorrow and bring better technologies to patients. We intend to continue to grow by bringing in the best talent, creating a centre of excellence in this area.”

In his new role, Dr Bradshaw (http://file///C:/Users/simon%20wadsworth/Dropbox%20(Igniyte%20L td)/Igniyte%20(1)/Online%20Reputation%20Management/Clients/Steven%20Brads haw/PR/MKTXS%20Appointment/about.me/drstevenbradshaw) will be advising pharmaceutical, medical device and biotechnology corporations on strategic global market access, evidence generation to best support health technologies, and other commercial initiatives. Matthew Kaye

PR Manager

Email -  press@kudos-pr.com

Phone - 0113 246 0183 Dr Steven Bradshaw’s credentials include being an expert advisor to think tanks across Europe, Japan, Latin America and UAE, and 8 years as a clinician in the National Health Service (NHS). Steven is the founding Director of Emedits Global, a scientific publication planning consultancy.

Steven has authored in excess of 30 scientific publications, including peer-reviewed journal articles, national clinical guidelines and invited editorials. Steven was Editor on the journal Nature Reviews Nephrology during 2010 and 2011, and he was a member of the Steering Committee of the Royal College of Physicians Clinical Guideline Development Group and NHS Plus in 2007 and 2008. Steven has delivered presentations at numerous conferences and training courses and has been an expert reviewer for many international journals.

Steven currently volunteers as a Mentor at AuthorAid, a charity that supports health researchers in developing countries.

Steven obtained his MB BChir from the University of Cambridge in the UK and he is a Member of the Royal College of Ophthalmologists. Steven also holds a BSc (Hons.) in Biochemistry from Leeds University.



This information was brought to you by Cision http://news.cision.com

http://news.cision.com/steven-bradshaw/r/global-healthcare-environment-strategy-firm-appoints-british-medical-research-expert-as-its-european,c9621783


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cision


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters